Of the 3473 patients with PCa who participated in the study, 2853 were excluded because they did not develop BCR, 12 were excluded for missing critical clinicopathological data, and 117 were excluded for having received neoadjuvant or adjuvant systemic therapy. This evidence concerns the gene BCR and posterior cortical atrophy.